Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer

M. Umemoto, Y. Yokoyama, S. Sato, S. Tsuchida, Fahd Al-Mulla, Y. Saito

Research output: Contribution to journalArticle

54 Citations (Scopus)


We have recently reported a novel function for carbonyl reductase (CR), namely, its ability to modulate the metastatic potential of malignant mouse cells. Because there are currently no data addressing a similar function for CR in human cancers, the aim of this study was to assess a correlation between survival and metastasis, and CR level in epithelial ovarian cancer. Using anti-CR antibody, immunohistochemical staining was performed on 73 epithelial ovarian cancers, 13 borderline malignant tumours, and 25 benign ovarian tumours for a total of 111 specimens. The combined rate for strongly and weakly positive reactions for CR was 32.0% for benign tumours, 38.5% for borderline malignant tumours, and 61.6% for ovarian cancers. The CR-positive rate was 35.7% (weakly positive alone) for ovarian cancers with retroperitoneal lymph node (RLN) metastasis and 67.8% for those without RLN metastasis (P < 0.05). The 5-year survival rate was 62.7% for the patients with CR-negative cancer and 86.1% for those with CR-positive cancer (P < 0.05). The present results indicate that decreased CR expression in epithelial ovarian cancer is associated with RLN metastasis and poor survival.

Original languageEnglish
Pages (from-to)1032-1036
Number of pages5
JournalBritish Journal of Cancer
Issue number7
Publication statusPublished - 28 Sep 2001



  • Carbonyl reductase
  • Epithelial ovarian cancer
  • Lymph node metastasis
  • Prognosis

Cite this